|  |
| --- |
| **Supplementary Table 1. Demographics and clinical characteristics for ASPIRE study and A5353 study.** |

| **Characteristics** | **ASPIRE (DTG+3TC)(n=18)** | **ASPIRE (3-drug)(n=20)** | **A5353 (DTG+3TC)(n=13)** |
| --- | --- | --- | --- |
| Age (years) |  |  |  |
|  Median (IQR) | 43 (35-56) |  47 (41-52) |  29 (25-40) |
| HIV RNA level at baseline (copies/ml) |  |  |  |
|  Median (IQR) |  <20 |  <20 |  29138 (13365-67968) |
| CD4+ at baseline (cells/µL) |  |  |  |
|  Median (IQR) |  663 (528-812) |  710 (484-872) |  458 (336-671) |
| Time on ART at baseline (years) |  |  |  |
|  Median (IQR)Self-reported ART adherence\*, n (%) | 5.4 (3.5-7.6) |  6.2 (3.8-7.8) |  ART naïve |
|  No missed doses | 11 (61%) | 11 (55%)  | 11 (85%) |
|    Missed some doses | 7 (40%) | 9 (45%) | 2 (15%) |
| Sex, n (%) |  |  |  |
|     Female | 3 (17%) | 2 (10%) | 1 (8%) |
|    Male | 15 (83%) | 18 (90%) | 12 (92%) |

**Legend:** IQR: Interquartile Range, ART: antiretroviral therapy, n: number, \* Self-reported ART Adherence during study follow-up

**Supplementary Figure 1. HIV RNA in genital secretion among ASPIRE and A5353 participants**

Levels of HIV RNA in genital secretion among A5353 antiretroviral-naïve participants who initiated DTG+3TC and virologically suppressed ASPIRE participants (divided by study arm, i.e. three-drug ART or switch to DTG+3TC). Lower limit of detection of the genital HIV RNA assay is 40 copies/ml.

